

KISUNLA™ Referral Form



Fax Completed Form To:

Phone:

PATIENT INFORMATION			
Patient Name:			Date of Birth:
Referral Date:	New Referral	Updated Order	Order Renewal
Address:			City/State/Zip:
Home Phone:	Cell Phone:		Work Phone:
Secondary Contact:	Height:	Weight:	Male Female
Allergies:			
Current Medications:			
Other Medical Conditions or Additional Comments:			
Medical History Related to IV Insertion (e.g. lymph nodes or mastectomy):			

DIAGNOSIS			
Patient Diagnosis & ICD-10:	G30.0 - Alzheimer's disease with early onset G30.9 - Alzheimer's disease, unspecified	G30.1 - Alzheimer's disease with late onset G31.84 - Mild cognitive impairment	G30.8 - Other Alzheimer's disease
Prescriber must indicate the following requirements have been met to confirm diagnosis & that Patient has evidence of AD neuropathology & has been assessed for baseline ARIA risk via MRI:			
Amyloid pathology confirmed via: Amyloid PET Scan -OR- CSF Analysis -OR- Blood plasma Result: Amyloid positive Amyloid negative (<i>Kisunla™ is not a treatment option for this Patient, if checked</i>)			Date:
Recent MRI obtained prior to initiating Kisunla™ (including FLAIR and T2/GRE or SWI) to assess ARIA risk Prescriber has verified that this Patient does not have evidence of prior ARIA-H			Date:
Completion of cognitive assessment type: MMSE MoCA CDR Other: Score: _____			Date:
Completion of functional assessment type: FAQ FAST Other: _____			Date:
Results for ApoE Testing			Date:
Completion of CMS approved CED registry (<i>only required for Patients with Medicare</i>) ClinicalTrials.gov Registry Number: NCT _____ Submission Number (<i>if applicable</i>): _____			CED Submission Date:
Note: MRIs must be obtained prior to initial infusion to assess ARIA risk. During treatment, conduct an ARIA monitoring MRI before Infusions 2, 3, 4 and 7 and if symptoms consistent with ARIA occur.			

PROVIDER INFORMATION		
Physician Name:	Lic.#:	DEA #:
Practice Name:	NPI#:	
Address:		City/State/Zip:
Office Contact:	Phone:	Fax:
Supervisory Physician (if applicable):		

PLEASE ATTACH	
Patient demographics & front/back copy of all insurance cards (prescription & medical) Recent office visit notes, history & physical, lab & pertinent procedure results Current medication list & list of prior medications tried and failed (with dates) Line access documentation/verification if applicable	Vaccine status (any vaccination) and documentation of any recent vaccinations Letter of medical necessity if drug dosing or indication is outside of FDA guidelines

NURSING & LAB ORDERS	
Nurse Orders: Nurse to provide assessment, teaching, lab draws, medication administration and vascular access device insertion and/or management per physician orders.	
Flush Orders: NaCl 0.9% - 5-10mL flush pre and post infusion and as needed Heparin - 10units/mL ---OR--- 100units/mL - 3-5mL flush after post-infusion NS flush if indicated to maintain line	
Lab Orders: Lab Date & Frequency:	

PRESCRIPTION ORDERS			
Anaphylaxis Kit: (Check all that apply)	Epinephrine 0.3mg IM as needed Diphenhydramine _____ mg IV as needed	Solu-cortef 250mg-500mg IV as needed NS Hydration 500 ml IV over 30 minutes as needed	Solu-Medrol 60mg - 125mg IV as needed Other _____
Pre-Medications: (Check all that apply)	Acetaminophen _____ mg PO _____ minutes prior to infusion Diphenhydramine _____ mg PO ---OR--- IV _____ minutes prior to infusion	Solu-Medrol _____ mg IV _____ minutes prior to infusion	Other _____
Supply Orders: All supplies for vascular access line care, drug administration kit(s), pump, and IV pole will be provided as necessary			

PRODUCT	PRESCRIPTION INFORMATION	REFILLS
Is this a first dose? Yes No	If No, when was last dose given? _____ When is patient due for next dose? _____	
KISUNLA	Induction: 700mg IV infusion via gravity ---OR--- pump over 30 minutes every 4 weeks x 3 doses	NONE
	Maintenance: 1400mg IV infusion via gravity ---OR--- pump over 30 minutes every 4 weeks If missed dose, administer the same dose as soon as possible and continue every 4 weeks. Obtain MRI prior to 2nd, 3rd, 4th, and 7th infusions. MRI results must be performed and cleared by MD to proceed to next infusion.	_____
	OTHER	NONE

By signing this form and utilizing our services, you are authorizing Amerita to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.

Prescriber's Signature _____
 Dispense as Written
 Print Name _____ Date _____

Prescriber's Signature _____
 Substitution Permitted
 Print Name _____ Date _____